IPIX MM Monthly ~ May 2018 May 2018 ~

New Post Public Reply Private Reply Replies (1) Message Board
4kids 4kids #3685
257
IPIX MM Monthly ~ May 2018







May 2018 ~ volume total ~ 5,542,951

April 2018 MM Monthly link:
https://investorshangout.com/post/view?id=5033179


there were 11 MMs/ECNs' reporting *activity* on IPIX .. in order:
ETRF/NITE/CDEL (32%/23%/22%)
CSTI/LAFC/ARCA/OTCX/VERT (5%/4%/4%/4%/3%)
CANT/MAXM/PUMA .. all less then 1%

amazing how much of a *decoy* both VERT & OTCX *were* ..

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 
IPIX Innovation Pharma 5,542,951 4,473,436 22,616,572 ETRF G1 EXECUTION SVCs, LLC 1,779,590 1 32.11
IPIX Innovation Pharma 5,542,951 4,473,436 22,616,572 NITE VIRTU AMERICAS LLC 1,288,265 2 23.24
IPIX Innovation Pharma 5,542,951 4,473,436 22,616,572 CDEL CITADEL SECURITIES LLC 1,224,386 3 22.09


it's been just about a year since mgmt's upside surprise in June 2017 .. here's the Monthly Volume Totals broken down by month .. take note of the *overlapping* similarities

JUN 2017 ~ 6,863,055
JUL 2017 ~ 4 ,896,207
AUG 2017 ~ 3 ,276,355
SEP 2017 ~ 2,395,379
OCT 2017 ~ 3 ,856,915
NOV 2017 ~ 4,0 31,082
DEC 2017 ~ 8,121,069
JAN 2018 ~ 5 ,133,221
FEB 2018 ~ 3 ,388,387
MAR 2018 ~ 4,0 78,577
APR 2018 ~ 4 ,473,436
MAY 2018 ~ 5 ,542,951

http://otce.finra.org/MonthlyShareVolume

during that same year long period .. *legal* had to be adjusted *upward* ..
(see below) .. but first .. i pulled the data (historical .. pps and volume avgs) from mid month for the last year >> to show patterns done on IPIX ..

5.15.17 ( markage @ 41% )
Detailed Quote:CTIX
CELLCEUTIX CORPORATION
0.82825Up 0.11825 (16.65 %) AS OF 3:58:26PM ET 05/15/2017


Volume 547,948
Volume (10 day Average) 140,183
Volume (90 day Average) 278,946


6.15.17 ( markage @ 24% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.76Up 0.02 (2.70 %)AS OF 3:57:28PM ET 06/15/2017


Volume 224,876
Volume (10 day Average) 336,072
Volume (90 day Average) 267,023


7.17.17 ( markage @ 23% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.972Down -0.068 (-6.54 %) AS OF 3:59:15PM ET 07/17/2017


Volume 249,885
Volume (10 day Average) 286,095
Volume (90 day Average) 276,468


8.15.17 ( markage @ 27% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.785Up 0.0565 (7.76 %) AS OF 3:57:24PM ET 08/15/2017


Volume 76,529
Volume (10 day Average) 161,964
Volume (90 day Average) 268,908


9.15.17 ( markage @ 22% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.72Up 0.0095 (1.34 %) AS OF 3:59:51PM ET 09/15/2017


Volume 223,443
Volume (10 day Average) 100,122
Volume (90 day Average) 227,459


10.16.17 ( markage @ 38% ) .. cracks starting to *show* (see below)
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.68Down -0.01 (-1.45 %) AS OF 3:59:59PM ET 10/16/2017


Volume 113,405
Volume (10 day Average) 168,465
Volume (90 day Average) 197,664


11.15.17 ( markage @ 15% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.69Down -0.015 (-2.13 %) AS OF 3:59:04PM ET 11/15/2017


Volume 163,194
Volume (10 day Average) 172,115
Volume (90 day Average) 164,764


12.15.17 ( markage @ 26% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.785Up 0.00705 (0.91 %) AS OF 3:59:57PM ET 12/15/2017


Price Performance (Last 52 Weeks)
12/14/2017 -32.35%


Volume 153,680
Volume (10 day Average) 563,214
Volume (90 day Average) 202,489


1.16.18 ( markage @ 32% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.7249Up 0.0149 (2.10 %) AS OF 3:59:25PM ET 01/16/2018


Price Performance (Last 52 Weeks)
01/12/2018 -39.06%


Volume 300,052
Volume (10 day Average) 244,424
Volume (90 day Average) 224,823


2.15.18 ( markage @ 36% ) ** 52 week low reset 2.22.18 (5.10.17)
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.69Up 0.005 (0.73 %) AS OF 3:56:07PM ET 02/15/2018


Price Performance (Last 52 Weeks)
02/14/2018 -31.50%


Volume 115,948
Volume (10 day Average) 159,451
Volume (90 day Average) 243,268


3.15.18 ( markage @ 27% )
DETAILED QUOTE:IPIX
INNOVATION PHARMACEUTICALS INC
0.57Down -0.03 (-5.00 %) AS OF 3:55:43PM ET 03/15/2018


PRICE PERFORMANCE (LAST 52 WEEKS)
03/14/2018 -35.48%


VOLUME 329,874
VOLUME (10 DAY AVERAGE) 210,605
VOLUME (90 DAY AVERAGE) 251,097


4.16.18 ( markage @ 57% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.50Down -0.007 (-1.38 %) AS OF 3:59:59PM ET 04/16/2018


Volume 295,972
Volume (10 day Average) 151,331
Volume (90 day Average) 243,964


5.15.18 ( markage @ 50% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.59005Up 0.15405 (35.33 %) AS OF 3:59:48PM ET 05/15/2018


Volume 384,483
Volume (10 day Average) 335,770
Volume (90 day Average) 218,697



===========================================

*legal* reported by NR on CTIX/IPIX since Jan 2017 ~ remember NR reset 52 week low on IPIX on 5.10.17 .. approx 1 month later mgmt did a *surprise* to NR by changing out name/ticker and cusip .. which took NR until 2.22.18 to *reset* ..

spot the *pattern* NR deployed on IPIX re: their *reporting* .. .. and note the whoppers' reported re: avg daily volume by NR .. Dec 2017 (among other months) comes to mind .. btw that *reporting* would *impact* those *days to cover* also *reported* by NR .. go figure



Settlement Date
Issue Name
Symbol
Market
Current Short
Previous Short
Chg
% Change from Prev
Avg Daily Vol
Days to Cover

 
05/15/2018 Innovation Pharma IPIX 1,194,881 1,113,653 81,228 7.29 677,661 1.76
04/30/2018 Innovation Pharma IPIX 1,113,653 1,131,509 -17,856 -1.58 536,933 2.07
04/13/2018 Innovation Pharma IPIX 1,131,509 1,105,305 26,204 2.37 302,523 3.74
03/29/2018 Innovation Pharma IPIX 1,105,305 1,107,705 -2,400 -0.22 328,260 3.37
03/15/2018 Innovation Pharma IPIX 1,107,705 1,146,037 -38,332 -3.34 442,762 2.5
02/28/2018 Innovation Pharma IPIX 1,146,037 1,147,767 -1,730 -0.15 419,357 2.73
02/15/2018 Innovation Pharma IPIX 1,147,767 1,122,033 25,734 2.29 310,620 3.7
01/31/2018 Innovation Pharma IPIX 1,122,033 1,121,161 872 0.08 494,222 2.27
01/12/2018 Innovation Pharma IPIX 1,121,161 1,119,374 1,787 0.16 479,712 2.34
12/29/2017 Innovation Pharma IPIX 1,119,374 1,125,087 -5,713 -0.51 517,994 2.16
12/15/2017 Innovation Pharma IPIX 1,125,087 1,129,343 -4,256 -0.38 1,046,247 1.08
11/30/2017 Innovation Pharma IPIX 1,129,343 1,140,375 -11,032 -0.97 428,497 2.64
11/15/2017 Innovation Pharma IPIX 1,140,375 1,274,605 -134,230 -10.53 342,258 3.33
10/31/2017 Innovation Pharma IPIX 1,274,605 1,227,218 47,387 3.86 361,557 3.53
10/13/2017 Innovation Pharma IPIX 1,227,218 1,214,663 12,555 1.03 335,578 3.66
09/29/2017 Innovation Pharma IPIX 1,214,663 1,214,089 574 0.05 262,229 4.63
09/15/2017 Innovation Pharma IPIX 1,214,089 1,220,108 -6,019 -0.49 215,861 5.62
08/31/2017 Innovation Pharma IPIX 1,220,108 1,226,343 -6,235 -0.51 262,819 4.64
08/15/2017 Innovation Pharma IPIX 1,226,343 1,206,257 20,086 1.67 307,793 3.98
07/31/2017 Innovation Pharma IPIX 1,206,257 1,302,241 -95,984 -7.37 389,777 3.09
07/14/2017 Innovation Pharma IPIX 1,302,241 1,458,432 -156,191 -10.71 609,859 2.14
06/30/2017 Innovation Pharma IPIX 1,458,432 1,234,237 224,195 18.16 594,048 2.46
06/15/2017 Innovation Pharma IPIX 1,234,237 1,161,877 72,360 6.23 650,213 1.9

05/31/2017 Cellceutix CTIX 1,161,877 1,037,384 124,493 12 579,670 2.0

 
May 15, 2017 1,037,384 18.46 354,459 2.93 No No
Apr 28, 2017 875,733 -0.07 759,565 1.15 No No
Apr 13, 2017 876,376 3.15 558,853 1.57 No No
Mar 31, 2017 849,619 -1.16 492,310 1.73 No No
Mar 15, 2017 859,596 -2.21 297,012 2.89 No No
Feb 28, 2017 879,016 0.82 796,211 1.10 No No
Feb 15, 2017 871,870 -0.34 373,962 2.33 No No
Jan 31, 2017 874,870 11.57 1,079,666 1.00 No No
Jan 13, 2017 784,114 -1.41 390,950 2.01 No No


NR had worked the cycle of money on CTIX (IPIX) *UP/DOWN* for years .. and most likely figured in early Jan 2015 .. that flip *DOWN* would be no different .. but a funny thing happened .. due to mgmt's ability to execute .. actual investors couldn't be parted from their *shares* and it set up *imo* the *events* by NR in the latter half of 2015 .. which mgmt didn't roll over for .. rather *aggressively responded* to .. and so it's gone since then .. this is why i note that NR is in a hole of their own making .. NR is used to always controlling *outcomes* on the OTC .. right now they have little time and imo even less *liquidity* .. which is why i say they are stuck .. and their *stuckness* is telegraphing itself via a *legal* that is almost amusing to watch *reported* .. bogus daily volume avgs reported re: that *legal* .. and daily *markages* ( % wise ) that keep ratcheting northward .. all this on less and less *volume* .. oh yeah and Innovation's multi platform hanging over NRs' *head* like the sword of damocles .. it couldn't happen to a nicer group of crooks *imo*

in pulling this post together (always time consuming) .. i realized i have the *legal reported* .. since Innovation first started trading .. way back when ..

if i have the time i will try and get that out sometime this week .. it's amazing how NRs' *cycles of money* .. worked for them so well for so long .. but nothing beats an aware OTC mgmt team that executes and an educated retail investor ..

best to all Innovation Pharma investors

4kids

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 78

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

XTransfer Partners with Shanghai Pudong Development Bank for Growth

Updated Category News Views 381

Collaboration on Cross-Border Financial Services XTransfer, recognized as a leading global B2B cross-border trade payment platform, is excited to announce its strategic partnership with Shanghai Pudong Development Bank Co. Ltd., Hong Kong Branch. This collaboration aims to enhance cross-border financial services tailored for SMEs engaged in international trade. Focus on...

Continue Reading
SmartOrderLink: Transforming B2B Order Transactions

Updated Category News Views 29

SmartOrderLink's Role in Streamlining B2B Transactions With every new business platform, there's the promise of smoother operations and less headache, and it seems like transcosmos and Kyoei Sangyo's SmartOrderLink might just cut through the chaos of B2B order transactions. Launched in Tokyo, this online order receipt platform promises to smarten up the process,...

Continue Reading
United Bancshares Sees Strong Start with Q1 2025 Results

Updated Category News Views 121

Financial Performance Overview United Bancshares, Inc. (OTCQX: UBOH) has announced significant financial achievements in early 2025, including a quarterly cash dividend declaration that reflects a solid growth trajectory. Quarterly Dividend and Earnings Highlights The Board has declared a cash dividend of $0.23 per share, marking a notable increase of 4.5%. This dividend,...

Continue Reading
Transforming Contact Center Operations: The Pulse Solution

Updated Category News Views 174

Unlock Business Potential with Pulse by OutboundIQ In the competitive matrix of today’s business landscape, effective decision-making is crucial for sustained growth. OutboundIQ has just become a pivotal player in enabling organizations to harness their data more effectively with the launch of Pulse. This innovative tool is designed specifically for contact centers,...

Continue Reading
Growth of Electronic Materials and Chemicals Market Insights

Updated Category News Views 144

Examining the Rapid Growth of the Electronic Materials and Chemicals Market The Electronic Materials and Chemicals Market is projected to reach an impressive USD 110.2 billion, fueled by consistent growth and a forecasted compound annual growth rate (CAGR) of 6.2% from 2024 to 2032. This increase is largely driven by significant advancements in electronic component...

Continue Reading